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Exposure to interfaces can accelerate aggregation of antibody therapeutics, particularly under stresses 
encountered during manufacture, transportation, and administration. Controlling interfacial antibody adsorption 
is critical to limiting aggregation. A panel of monoclonal antibody therapeutics was characterized by multiple 
surface-sensitive techniques to predict their risk of interfacially mediated aggregation. The antibodies with the 
highest interfacial aggregation propensity exhibited more than a five-fold faster rate of surface pressure increase 
and rapidly formed hydrophobic films upon adsorption, which indicated these molecules unfolded rapidly at the 
interface. Strong, essentially irreversible protein-protein interactions, likely dominated by hydrophobic 
interactions, resulted in high levels of aggregation for these antibodies. In contrast, the antibodies with a low 
propensity to aggregate at the interface required many minutes of interfacial exposure to form hydrophobic films 
and did not develop strong, irreversible interactions. Overall, characterization of the interfacial properties of the 
antibodies allowed us to predict their extent of interfacial aggregation. 
 
The risk of interfacial aggregation measured using surface-sensitive techniques was then related to the level of 
surfactant required in a formulation to stabilize against aggregation. Specifically, a small-scale IV bag agitation 
model was used to assess aggregation after simulated handling and transportation in the clinic. The level of 
surfactant required to stabilize against the agitation stress correlated directly with the risk of interfacial 
aggregation of the antibody, suggesting that surface-sensitive techniques can be used to enable rapid surfactant 
screening during formulation development. 
 
